First-in-human study of intravenous bispecific CTLA-4 × OX40 antibody (ATOR-1015) in advanced solid malignancies
Background: Ipilimumab, a monoclonal antibody against cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), was the first approved checkpoint inhibitor; however, its use is hampered by treatment-related adverse events (TRAEs). ATOR-1015 is a bispecific antibody targeting CTLA-4 and OX40 designed to direct the effect to the tumor microenvironment and thereby improve the response rate and reduce TRA
